Product Information
IBANDRONATE SODIUM 150 MG TAB is a generic product labeled by Aurobindo Pharma Limited, priced at $2.6751 per EA under NDC 65862023703. Its NADAC has been published 508 times since Jan 11, 2017.
FDA first approved this application on Mar 11, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862023703
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBANDRONATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA204502FDA Approved
3/11/2016
TE Code
AB
On Market Since
3/11/2016
Pharmacological Classes
Price Statistics
The NADAC for IBANDRONATE SODIUM 150 MG TAB has been published 508 times since Jan 11, 2017, and over the history we have for it it has declined 82.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6751 per EA |
|---|---|
| All-time high | $15.6377 (Jan 11, 2017) |
| All-time low | $2.6751 (Sep 23, 2026) |
| 52-week high | $3.0795 |
| 52-week low | $2.6751 |
| Median price | $5.5309 |
| Average price | $5.8266 |
| Largest weekly change | -37.5% (Nov 20, 2024) |
| Weeks tracked | 508 |
| Tracking since | Jan 11, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Ibandronate Sodium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibandronate Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bisphosphonate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBANDRONATE SODIUM 150 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IBANDRONATE SODIUM 150 MG TAB, manufactured by Aurobindo Pharma Limited, is $2.6751 per EA (NDC 65862023703), effective Sep 30, 2026.
How has the price of IBANDRONATE SODIUM 150 MG TAB changed over time?
Over the history we have for it, the NADAC for IBANDRONATE SODIUM 150 MG TAB has declined 82.9%. It has been tracked across 508 weekly CMS publications since Jan 11, 2017.
What are the highest and lowest recorded NADAC prices for IBANDRONATE SODIUM 150 MG TAB?
Since Jan 11, 2017, the NADAC for IBANDRONATE SODIUM 150 MG TAB has ranged from a low of $2.6751 (Sep 23, 2026) to a high of $15.6377 (Jan 11, 2017), with a median of $5.5309 per EA.
Are there cheaper alternatives to IBANDRONATE SODIUM 150 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of IBANDRONATE SODIUM 150 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures IBANDRONATE SODIUM 150 MG TAB?
IBANDRONATE SODIUM 150 MG TAB (NDC 65862023703) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.